Alembic Pharma's (ALPM) Q1FY18 results were below estimates due to 21% YoY decline in India revenue (estimate: 12% YoY decline) on channel destocking ahead of GST rollout. Management expects gradual restocking in the trade channel, and subsequent volume recovery through Q2'18. US sales declined ..